Recent developments include quarterly earnings reports showing continued net losses with revenue growth, ongoing clinical research, and active market coverage by analysts.

• PROCEPT reported a net loss and revenue below estimates for Q3 2026 [N1].
• Analysts have initiated coverage with various recommendations reflecting market interest [N2].
• Q2 2026 earnings call transcripts and highlights detailed operational and financial results [N3][N4][N5].
• The company continues to invest in clinical research and product innovation [N6].
• Q1 2026 earnings transcripts and reports showed revenue growth with net losses [N7][N8].

PROCEPT BioRobotics benefits from a large and growing addressable market driven by the prevalence of BPH and aging demographics. Its technology offers a differentiated, clinically supported treatment option with favorable safety and efficacy profiles. The company's expanding installed base, strong payor coverage, and ongoing clinical research, including prostate cancer trials, support potential broader adoption. Investments in R&D and AI integration may enhance product capabilities and usability. International expansion efforts and increased awareness beyond urology could further extend market reach.

PROCEPT BioRobotics operates in a competitive medical device market with ongoing net losses and a significant accumulated deficit. Adoption of its technology depends on continued acceptance by urologists, payors, and patients, which may be challenged by entrenched alternatives and reimbursement dynamics. The company faces execution risks in scaling sales, expanding coverage, and advancing clinical research. Market penetration outside the U.S. remains limited. Financial performance is sensitive to operational execution and market conditions, with no guarantee of profitability or sustained revenue growth.

PROCEPT BioRobotics' moat is built on its proprietary AquaBeam and HYDROS robotic systems delivering Aquablation therapy, which is supported by a robust body of clinical evidence demonstrating superior safety and non-inferior efficacy compared to traditional surgical treatments. The therapy's unique combination of image-guided, automated robotic resection independent of prostate size and surgeon experience differentiates it from alternatives. Favorable Medicare and commercial payor coverage, inclusion in clinical guidelines, and a growing installed base strengthen market adoption. The company's direct sales force and strategic relationships with key opinion leaders and urological societies further support competitive positioning.

• Market Adoption Risk: The company's growth depends on adoption of Aquablation therapy by urologists and hospitals, which may be affected by competition, physician preferences, and reimbursement policies.
• Financial Risk: PROCEPT has incurred significant net losses and an accumulated deficit, with ongoing cash burn requiring effective capital management and operational execution.
• Regulatory and Reimbursement Risk: Changes in Medicare or commercial payor coverage policies could impact patient access and revenue. Regulatory approvals and clinical trial outcomes also pose risks.
• Operational Execution Risk: Scaling the direct sales force, expanding international presence, and advancing clinical research require successful execution and resource allocation.

• PROCEPT BioRobotics Corp is a surgical robotics company focused on developing and commercializing robotic systems for minimally invasive urologic surgery, specifically targeting benign prostatic hyperplasia (BPH) [S1].
• The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which deliver Aquablation therapy combining real-time imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation [S1].
• Aquablation therapy is designed to provide effective, safe, and durable symptom relief for males with lower urinary tract symptoms due to BPH, independent of prostate size, shape, and surgeon experience [S1].
• As of December 31, 2025, PROCEPT had an installed base of 912 robotic systems globally, including 718 in the United States [S1].
• The company estimates a total addressable market opportunity of approximately $30 billion in the United States, including men receiving drug therapy, those who have failed medication, and those undergoing surgical intervention [S1].
• PROCEPT generated revenues of $308.1 million and $224.5 million for the years ended December 31, 2025 and 2024, respectively, and incurred net losses of $95.6 million and $91.4 million for the same periods [S1].
• As of December 31, 2025, the company had an accumulated deficit of $641.6 million [S1].
• The company primarily sells its products through a direct sales organization targeting urologists in approximately 2,700 hospitals in the United States performing resective BPH procedures [S1].
• PROCEPT has established favorable Medicare coverage for Aquablation therapy across all 50 states and estimates access to approximately 95% of men in the United States through commercial payors [S1].
• The company is investing in clinical research, including prostate cancer trials, and in R&D to improve and innovate its robotic systems and integrate AI and machine learning [S1].
• Liquidity snapshot as of September 30, 2026: cash and equivalents of $218.4 million, current assets of $414.2 million, current liabilities of $70.4 million, current ratio of 5.89, and cash ratio of 3.1 [S2].
• For the nine months ended September 30, 2026, PROCEPT reported a net loss of $26.5 million and basic and diluted EPS of -$0.46 [S2].
• Recent quarterly earnings reports indicate continued net losses but revenue growth, with Q3 2026 reporting a loss and lagging revenue estimates [N1].
• The company has ongoing efforts to expand private payor coverage and international market presence [S1].
• PROCEPT's clinical evidence includes nine clinical studies and over 150 peer-reviewed publications supporting Aquablation therapy's efficacy and safety [S1].
• Aquablation therapy has demonstrated superior safety and non-inferior efficacy compared to the historical standard of care, TURP, with low surgical retreatment rates [S1].
• The company focuses on increasing system utilization by converting urologists' resective cases to Aquablation therapy and expanding awareness beyond urology to primary care physicians [S1].
• Recent news includes multiple earnings call transcripts and coverage initiation by analysts, reflecting active market interest [N2, N3, N4, N5, N7, N8].